Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-Carvedilol
- Development stage
- Phase 3
- Lead developer
- AHN-GOOK PHARMACEUTICAL
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AGSCT101 is the S-enantiomer of carvedilol, developed by Ahn-Gook Pharmaceutical as an incrementally modified drug product for the treatment of essential hypertension. It acts as a beta-adrenoceptor antagonist (beta-blocker), targeting β-adrenoceptors to lower blood pressure. The drug is classified as an antihypertensive and is administered orally. It was launched in South Korea for essential hypertension before March 2018 and represents a new formulation rather than a new molecular entity[1][4][5][7].
- Other names
- s-carvedilol
02
Targets
ADRB2 (β2)ADRB1 (β1)
Beyond the preview
Go deeper on S-Carvedilol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S-Carvedilol.